Newsroom

News and Media

Recent Press Releases

Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering
Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR
Vallon Pharmaceuticals Announces Issuance of Japanese Patent Covering Composition of Matter and Methods of Manufacturing for ADAIR
Vallon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Vallon Pharmaceuticals Announces Review of Strategic Alternatives
Vallon Pharmaceuticals to Participate at the 5th Annual Neuroscience Innovation Forum
Vallon Pharmaceuticals Announces Topline Results of its Pivotal SEAL Study for Lead Program, ADAIR, for the Treatment of ADHD
Vallon Pharmaceuticals Announces Appointment of Meenu Karson to Board of Directors
Vallon Pharmaceuticals Announces Issuance of U.S. Patent Covering ADAIR for the Treatment of Cognitive Impairment Associated with COVID-19
Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update
Vallon Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference
Vallon Pharmaceuticals Presents New Data from Adult Stimulant Abuse Pattern Survey at the APSARD 2022 Annual Conference
Vallon Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference
Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR
Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Vallon Pharmaceuticals to Present at the Virtual Investor Roundtable Event
Vallon Pharmaceuticals to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference
Vallon Pharmaceuticals Presents Data from Adult Stimulant Abuse Pattern Survey at the American Academy of Child and Adolescent Psychiatry (AACAP) 68th Annual Meeting
Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements
Vallon Pharmaceuticals Announces Formation of Scientific Advisory Board
Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit
Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIR
Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
Vallon Pharmaceuticals Appoints Leanne Kelly as Chief Financial Officer
Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit
Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum
Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval
Vallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update
Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors
Vallon Pharmaceuticals Announces Closing of Initial Public Offering
Vallon Pharmaceuticals Announces Pricing of Initial Public Offering
Vallon Pharmaceuticals Announces Presentation of ADAIR Pharmacokinetics and Pharmacodynamic Data at the Virtual 2021 APSARD Annual Meeting
Data from Vallon Pharmaceuticals’ ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting
Vallon Pharmaceuticals Presents Positive Data from Proof-of-Concept Intranasal Human Abuse Study of Its Investigational ADHD Stimulant, ADAIR

Media Contact

JTC Team, LLC
Jenene Thomas
(833) 475-8247
vallon@jtcir.com

Subscribe to Receive News Alerts